Spain's Ministry of Health has approved the funding for subcutaneous atezolizumab, the first and only cancer immunotherapy available for subcutaneous injection.

This new method reduces administration time from 30-60 minutes to just 4-8 minutes, benefiting over 38,000 European patients annually who receive this therapy for various cancers.

The subcutaneous injection is preferred by 79% of patients and 90% of healthcare professionals find it easier to administer.

This innovation is expected to improve patient quality of life, increase treatment adherence, and contribute to the sustainability of the National Health System by optimizing treatment times and resource use.